In vitro antibacterial activity of sulbactam/durlobactam and eravacycline against Acinetobacter

doi:10.3969/j.issn.1673-8640.2026.07.004

Abstract

Abstract:

Objective To evaluate the in vitro antibacterial activity of sulbactam/durlobactam（SUL/DUR）and eravacycline（ERV）against Acinetobacter. Methods A total of 124 Acinetobacter isolates isolated from clinical specimens at Zhongshan Hospital of Fudan University from February to March 2025 were collected. The species were identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The in vitro drug susceptibility was determined by automated bacterial susceptibility testing system. The minimum inhibitory concentrations（MIC）of conventional antibacterial agents for Acinetobacter baumannii（AB）were determined by broth microdilution and disk diffusion methods. The drug resistance genotypes of SUL/DUR-resistant Acinetobacter were determined by immunochromatography. Fourier transform infrared spectroscopy was used for homology analysis of SUL/DUR non-susceptible Acinetobacter. Hierarchical cluster analysis was performed using the unweighted group average method model，and a dendrogram was generated. Results The 84 of 124 Acinetobacter isolates were AB. The drug resistance rates of 84 AB isolates to tigecycline（TGC），ERV，colistin（COL）and SUL/DUR were 2.38%，3.57%，3.57% and 16.67%，respectively. Among the 16 SUL/DUR non-sensitive AB isolates，12 of them were bla_NDM-producing beta-lactamases. The isolation rate of carbapenem-resistant Acinetobacter baumannii（CRAB）was 97.61%（82/84）. The drug resistance rates of 40 other Acinetobacter species to TGC，ERV，COL and SUL/DUR were 0，0，2.5% and 2.5%，respectively. Additionally，the MIC₅₀ and MIC₉₀ of SUL/DUR against AB were 2 and 64 μg·mL^-1，respectively，and those of ERV were 0.25 and 0.50 μg·mL^-1，respectively. The MIC₅₀ and MIC₉₀ of SUL/DUR against other Acinetobacter species were 1 and 4 μg·mL^-1，respectively，and those of ERV were 0.32 and 0.64 μg·mL^-1，respectively. Conclusions SUL/DUR and ERV have good in vitro antibacterial activity against Acinetobacter.

Key words: Acinetobacter baumannii, Sulbactam/durlobactam, Eravacycline, In vitro antibacterial activity

CLC Number:

R378.99

GAO Hongzhi, CAO Jinnan, HUANG Shenglei, ZHOU Chunmei, ZHOU Jiaye, WANG Beili, PAN Baishen, GUO Wei. In vitro antibacterial activity of sulbactam/durlobactam and eravacycline against Acinetobacter[J]. Laboratory Medicine, 2026, 41(7): 637-642.

Figures/Tables 5

References 34

[1]	He J, Hong L, Song M, et al. Diverse Acinetobacter species and plasmid-driven spread of carbapenem resistance in pharmaceutical settings in China[J]. Environ Int, 2025, 29(3):107-115.
[2]	Sheck E, Romanov A, Shapovalova V, et al. Acinetobacter non-baumannii species:occurrence in infections in hospitalized patients,identification,and antibiotic resistance[J]. Antibiotics(Basel), 2023, 12(8):1301.
[3]	Shi J, Cheng J, Liu S, et al. Acinetobacter baumannii:an evolving and cunning opponent[J]. Front Microbiol, 2024, 15(2):108-133.
[4]	Wong D, Nielsen T B, Bonomo R A, et al. Clinical and pathophysiological overview of Acinetobacter infections:a century of challenges[J]. Clin Microbiol Rev, 2017, 30(1):409-447. DOI URL
[5]	Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii:a review of microbiological,virulence,and resistance traits in a threatening nosocomial pathogen[J]. Antibiotics(Basel), 2020, 9(3):119.
[6]	梁亮, 刘晓春, 陈杏春, 等. 鲍曼不动杆菌血流感染预后危险因素分析[J]. 华西医学, 2021, 36(1):76-81.
[7]	中国细菌耐药监测网. 抗生素耐药性[EB/OL]. (2025-03-15)[2025-06-14]. https://www.chinets.com/Data/AntibioticDrugFast.
[8]	全国细菌耐药监测网. 2021年全国细菌耐药监测网重症监护病房临床分离细菌耐药监测报告[J]. 中华医院感染学杂志, 2023, 33(22):3370-3379.
[9]	李国庆, 陶倩, 李国辉. 耐碳青霉烯类鲍曼不动杆菌感染的治疗进展[J]. 中国抗生素杂志, 2024, 49(8):841-850.
[10]	Asif M, Alvi I A, Rehman S U. Insight into Acinetobacter baumannii:pathogenesis,global resistance,mechanisms of resistance,treatment options,and alternative modalities[J]. Infect Drug Resist, 2018, 11:1249-1260. DOI URL
[11]	李琰冰, 周梦兰, 徐英春. 多黏菌素异质性耐药机制研究进展[J]. 协和医学杂志, 2025, 16(1):177-183.
[12]	Zha L, Pan L, Guo J, et al. Effectiveness and safety of high dose tigecycline for the treatment of severe infections:a systematic review and meta-analysis[J]. Adv Ther, 2020, 37(3):1049-1064. DOI
[13]	王婷, 崔小康, 李敏, 等. 山东省近10年替加环素致严重不良反应分析[J]. 药学研究, 2024, 43(10):1035-1040.
[14]	Yaghoubi S, Zekiy A O, Krutova M, et al. Tigecycline antibacterial activity,clinical effectiveness,and mechanisms and epidemiology of resistance:narrative review[J]. Eur J Clin Microbiol Infect Dis, 2022, 41(7):1003-1022. DOI
[15]	马兴换. 新型广谱四环素类抗生素依拉环素的研究[J]. 国外医药(抗生素分册), 2025, 46(1):39-44.
[16]	国家药监局批准注射用舒巴坦钠/注射用度洛巴坦钠组合包装上市[EB/OL]. (2024-05-20)[2025-06-17]. https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20240520091748157.html.
[17]	Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. M100-ed34,CLSI, 2024.
[18]	国家卫生健康委临床抗微生物药物敏感性折点研究和标准制定专家委员会, 中国医院协会临床微生物实验室专业委员会, 欧洲临床微生物与感染病学会药敏委员会华人药敏试验委员会, 等. 依拉环素体外药物敏感性试验规范(2025)[J]. 中华检验医学杂志,2025, 48(6):693-700.
[19]	中国医疗保健国际交流促进会临床微生物与感染分会, 中华医学会检验医学分会临床微生物学组, 中华医学会微生物学与免疫学分会临床微生物学组. 多黏菌素类与替加环素及头孢他啶/阿维巴坦药敏方法和报告专家共识[J]. 中华检验医学杂志, 2020, 43(10):964-972.
[20]	欧洲抗菌药物敏感性试验标准委员会. MIC和抑菌圈直径解释折点表:Version 15.0[EB/OL].(2025-01-01)[202-06-14]. https://www.Eucast.org/clinical_breakpoints/.
[21]	史欣玥, 张定宇. 鲍曼不动杆菌相关耐药机制及新型治疗手段[J]. 西南医科大学学报, 2025, 48(1):97-104.
[22]	Luo Q, Lu P, Chen Y, et al. ESKAPE in China:epidemiology and characteristics of antibiotic resistance[J]. Emerg Microbes Infect, 2024, 13(1):2317915 DOI URL
[23]	Findlay J, Poirel L, Bouvier M, et al. In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance[J]. J Glob Antimicrob Resist, 2022, 30:445-450. DOI URL
[24]	杨君, 刘芳, 喻明洁, 等. 复方β-内酰胺酶抑制剂舒巴坦/度洛巴坦[J]. 中国新药杂志, 2025, 34(3):244-248.
[25]	Kaye K S, Shorr A F, Wunderink R G, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex:a multicentre,randomised,active-controlled,phase 3,non-inferiority clinical trial (ATTACK)[J]. Lancet Infect Dis, 2023, 23(9):1072-1084. DOI URL
[26]	Wang M, Ge L, Chen L, et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant Acinetobacter baumannii among patients from different global regions[J]. Clin Infect Dis, 2024, 78(2):248-258. DOI URL
[27]	Karlowsky J A, Hackel M A, Mcleod S M, et al. In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021[J]. Antimicrob Agents Chemother, 2022, 66(9):e00781-22.
[28]	Yang Q, Xu Y, Jia P, et al. In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China[J]. J Antimicrob Chemother, 2020, 75(7):1833-1839. DOI URL
[29]	全国细菌耐药监测网. 2023年全国细菌耐药监测报告(简要版)[EB/OL].(2024-11-18)[2025-06-05]. https://www.carss.cn/Report/Details/978.
[30]	Paul M, Carrara E, Retamar P, et al. European society of clinical microbiology and infectious diseases (ESCMID)guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli[J]. Clin Microbiol Infect, 2022, 28(4):521-547. DOI URL
[31]	Hawser S, Kothari N, Monti F, et al. In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020[J]. J Glob Antimicrob Resist, 2023, 33:304-320. DOI URL
[32]	Zhao C, Wang X, Zhang Y, et al. In vitro activities of eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China[J]. BMC Infect Dis, 2019, 19(1):508. DOI
[33]	潘姿彤, 李荷楠. 依拉环素耐药机制的研究进展[J]. 中华医院感染学杂志, 2023, 33(23):3674-3680.
[34]	Shi Y, Hua X, Xu Q, et al. Mechanism of eravacycline resistance in Acinetobacter baumannii mediated by a deletion mutation in the sensor kinase adeS,leading to elevated expression of the efflux pump AdeABC[J]. Infect Genet Evol, 2020, 80:104185. DOI URL

抗菌药物	敏感	中介^①	耐药
IPM	2.38	0	97.62
MEM	2.38	0	97.62
TZP	2.38	0	97.62
CAZ	2.38	0	97.62
CIP	2.38	0	97.62
FEP	2.38	1.19	96.43
SAM	7.14	1.19	91.67
AMK	7.14	2.38	90.48
TOB	9.52	1.19	89.29
LEV	8.33	2.38	89.29
DOX	10.71	0	89.29
SCF	5.95	17.86	76.19
SXT	36.90	0	63.10
MNO	20.24	21.43	58.33
SUL/DUR	80.95	2.38	16.67
COL	96.43	0	3.57
ERV	96.43	0	3.57
TGC	96.43	1.19	2.38

抗菌药物	敏感	中介^①	耐药
IPM	2.38	0	97.62
MEM	2.38	0	97.62
TZP	2.38	0	97.62
CAZ	2.38	0	97.62
CIP	2.38	0	97.62
FEP	2.38	1.19	96.43
SAM	7.14	1.19	91.67
AMK	7.14	2.38	90.48
TOB	9.52	1.19	89.29
LEV	8.33	2.38	89.29
DOX	10.71	0	89.29
SCF	5.95	17.86	76.19
SXT	36.90	0	63.10
MNO	20.24	21.43	58.33
SUL/DUR	80.95	2.38	16.67
COL	96.43	0	3.57
ERV	96.43	0	3.57
TGC	96.43	1.19	2.38

抗菌药物	敏感	中介	耐药
CAZ	70.00	7.50	22.50
FEP	72.50	5.00	22.50
CIP	77.50	10.00	12.50
TZP	80.00	7.50	12.50
IPM	82.50	2.50	15.00
MEM	82.50	0	17.50
SXT	82.50	0	17.50
TOB	90.00	10.00	0
LEV	90.00	2.50	7.50
SCF	92.50	2.50	5.00
SAM	92.50	0	7.50
AMK	97.50	0	2.50
SUL/DUR	97.50	0	2.50
COL	97.50	0	2.50
DOX	100.00	0	0
MNO	100.00	0	0
ERV	100.00	0	0
TGC	100.00	0	0

抗菌药物	敏感	中介	耐药
CAZ	70.00	7.50	22.50
FEP	72.50	5.00	22.50
CIP	77.50	10.00	12.50
TZP	80.00	7.50	12.50
IPM	82.50	2.50	15.00
MEM	82.50	0	17.50
SXT	82.50	0	17.50
TOB	90.00	10.00	0
LEV	90.00	2.50	7.50
SCF	92.50	2.50	5.00
SAM	92.50	0	7.50
AMK	97.50	0	2.50
SUL/DUR	97.50	0	2.50
COL	97.50	0	2.50
DOX	100.00	0	0
MNO	100.00	0	0
ERV	100.00	0	0
TGC	100.00	0	0

MIC	AB	其他不动杆菌
≥64 μg·mL^-1	12（14.28）	1（2.50）
32 μg·mL^-1	2（16.66）	0（2.50）
16 μg·mL^-1	0（16.66）	0（2.50）
8 μg·mL^-1	2（19.04）	0（2.50）
4 μg·mL^-1	25（48.80）	8（22.50）
2 μg·mL^-1	27（80.95）	2（27.50）
1 μg·mL^-1	10（92.86）	10（52.50）
0.5 μg·mL^-1	5（98.81）	6（67.50）
≤0.25 μg·mL^-1	1（100.00）	13（100.00）